Initial Strategies in Advanced HCC: Case 2
Initial Strategies in Advanced HCC
June 2015
- A 62-year old female smoker with a history of alcoholism and type 2 diabetes, HTN is experiencing fatigue
- ECOG=1
- Child-Pugh A
- T bilirubin 1.4; albumin 3.8; INR 1.1; no ascites, no encephalopathy; platelets 94
- CT scan reveals one 6-cm liver mass with invasion into the right branch of the portal vein, metastatic disease involving the abdominal lymph nodes and lung
- Biopsy confirmed HCC diagnosis; poorly differentiated
- Patient admitted nonadherence to anti-hypertensive medications
- Therapy was initiated with sorafenib at 400 mg BID
- Patient experienced grade 1 HTN, fatigue, dyspepsia, grade 3 diarrhea
- Dose was reduced to 400 mg QD, antimotility agents were given
- Patient was counselled regarding diet
July 2016
- Follow-up imaging has shown stable disease
- ECOG=1
- Patient is now Child-Pugh B
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More
